Ovid Therapeutics Book Value 2011-2026 | OVID

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Ovid Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
131 M	68.2 M	87.8 M	132 M	180 M	43.6 M	70 M	38.8 M	83.4 M	49.3 M	68.1 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
180 M	38.8 M	86.5 M

Quarterly Book Value Ovid Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
44.7 M	55.8 M	59.3 M	68.2 M	76.3 M	88.9 M	78.3 M	87.8 M	101 M	111 M	121 M	132 M	142 M	152 M	165 M	180 M	197 M	207 M	221 M	43.6 M	43.6 M	43.6 M	43.6 M	70 M	70 M	70 M	70 M	38.8 M	38.8 M	38.8 M	38.8 M	89.5 M	89.5 M	89.5 M	89.5 M	53 M	53 M	53 M	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
221 M	38.8 M	88.9 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-683 M	$ 9.13	-0.76 %	$ 591 M	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	13.8 M	$ 0.91	2.42 %	$ 6.69 M	China
Edesa Biotech EDSA	1.98 M	$ 15.52	-2.39 %	$ 49.6 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	733 M	$ 22.47	1.19 %	$ 3.72 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Fortress Biotech FBIO	62.2 M	$ 2.24	0.9 %	$ 62.5 M	USA
Galectin Therapeutics GALT	-126 M	$ 2.26	0.22 %	$ 144 M	USA
Galapagos NV GLPG	3.24 B	$ 28.07	0.75 %	$ 2.69 B	Belgium
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Grifols, S.A. GRFS	8.61 B	$ 8.2	3.6 %	$ 6.83 B	Spain
Harmony Biosciences Holdings HRMY	870 M	$ 31.01	-0.13 %	$ 1.78 B	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
ImmuCell Corporation ICCC	27.1 M	$ 8.44	-	$ 76.2 M	USA
InflaRx N.V. IFRX	41.6 M	$ 1.95	-1.77 %	$ 152 M	Germany
Immuron Limited IMRN	23.2 M	$ 0.83	3.44 %	$ 6.55 M	Australia
Incyte Corporation INCY	5.17 B	$ 98.87	-0.23 %	$ 19.3 B	USA
InMed Pharmaceuticals INM	12.1 M	$ 0.71	1.28 %	$ 1.74 M	Canada
INmune Bio INMB	23.5 M	$ 1.35	1.5 %	$ 33.4 M	USA
Innoviva INVA	1.64 B	$ 23.13	0.35 %	$ 1.56 B	USA
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Brainstorm Cell Therapeutics BCLI	-9.98 M	-	-2.5 %	$ 5.88 M	USA
BioNTech SE BNTX	19.2 B	$ 104.54	2.92 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Jaguar Health JAGX	-18.7 M	$ 7.55	-4.13 %	$ 17.6 M	USA
KalVista Pharmaceuticals KALV	-2.71 M	$ 26.67	-0.02 %	$ 1.44 B	Britain
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Innate Pharma S.A. IPHA	267 M	$ 1.43	-4.03 %	$ 235 M	France
Kamada Ltd. KMDA	319 M	$ 8.15	0.49 %	$ 260 M	Israel
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Kazia Therapeutics Limited KZIA	18.6 M	$ 13.24	6.56 %	$ 1.75 B	Australia
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Ligand Pharmaceuticals Incorporated LGND	830 M	$ 223.98	-0.39 %	$ 4.1 B	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.22	7.69 %	$ 5.3 M	Israel
Liquidia Corporation LQDA	44.7 M	$ 38.39	0.62 %	$ 3.3 B	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aquestive Therapeutics AQST	-33.7 M	$ 4.08	0.74 %	$ 436 M	USA